Opiant Announces Publication of Manuscript Treatment of Overdose in the Synthetic Opioid Era in Peer-Reviewed Journal Pharmacology & Therapeutics
November 02, 2021 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a company advancing medicines to better treat addictions and drug overdose, today...
Opiant Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021
October 21, 2021 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals to Participate in September Investor Conferences
August 25, 2021 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT) today announced that members of the company’s senior management team will participate...
Opiant Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 05, 2021 16:01 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
July 22, 2021 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 20, 2021 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...
Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer
July 12, 2021 08:00 ET
|
Opiant Pharmaceuticals, Inc.
Mr. Ruth led the highly successful launch and commercialization of the first FDA-approved nasal naloxone spray to treat opioid overdoseHe joins Opiant at a time when the Company is developing and...
Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel Investigational Treatment for Opioid Overdose
July 06, 2021 16:01 ET
|
Opiant Pharmaceuticals, Inc.
Data demonstrate rapid absorption and higher plasma concentrations versus an intramuscular injection (p<0.0001) Results confirm findings of initial pilot PK studySANTA MONICA, Calif., July 06, 2021...
Opiant Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference
May 24, 2021 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals to Hold Virtual 2021 Annual Shareholder Meeting on Tuesday, June 15, 2021 at 9:00am PDT
May 18, 2021 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug...